You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 11,077,106


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,077,106 protect, and when does it expire?

Patent 11,077,106 protects BALVERSA and is included in one NDA.

This patent has thirty-two patent family members in twenty-seven countries.

Summary for Patent: 11,077,106
Title:Cancer treatment
Abstract: The present invention provides a method for the treatment of cancer with erdafitinib.
Inventor(s): Stuyckens; Kim (Heist-op-den-berg, BE), Perez Ruixo; Juan Jose (Valencia, ES), De Porre; Peter Marie Z. (Sint-Denijs-Westrem, BE), Avadhani; Anjali Narayan (Chalfont, PA), Loriot; Yohann (Villejuif, FR), Siefker-Radtke; Arlene O. (Pearland, TX)
Assignee: Janssen Pharmaceutica NV (Beerse, BE)
Application Number:16/483,579
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;

Recent additions to Drugs Protected by US Patent 11,077,106

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Janssen Biotech BALVERSA erdafitinib TABLET 212018 Apr 12, 2019 RX Yes ⤷  Try a Trial ⤷  Try a Trial U-3196 TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS, AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY, WITH DOSING BASED ON SERUM PHOSPHATE LEVELS
Janssen Biotech BALVERSA erdafitinib TABLET 212018 Apr 12, 2019 RX Yes ⤷  Try a Trial ⤷  Try a Trial U-3808 TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER AT LEAST ONE LINE OF PRIOR SYSTEMIC THERAPY, WITH DOSING BASED ON SERUM PHOSPHATE LEVELS
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 11,077,106

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-001 Apr 12, 2019 RX Yes No ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS, AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY, WITH DOSING BASED ON SERUM PHOSPHATE LEVELS ⤷  Try a Trial
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-002 Apr 12, 2019 RX Yes No ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS, AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY, WITH DOSING BASED ON SERUM PHOSPHATE LEVELS ⤷  Try a Trial
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-003 Apr 12, 2019 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS, AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY, WITH DOSING BASED ON SERUM PHOSPHATE LEVELS ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 11,077,106

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
17209098Dec 20, 2017
PCT Information
PCT FiledFebruary 02, 2018PCT Application Number:PCT/EP2018/052694
PCT Publication Date:August 09, 2018PCT Publication Number: WO2018/141921

International Family Members for US Patent 11,077,106

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2018216969 ⤷  Try a Trial
Brazil 112019016043 ⤷  Try a Trial
Canada 3049737 ⤷  Try a Trial
China 110198716 ⤷  Try a Trial
Denmark 3576740 ⤷  Try a Trial
Eurasian Patent Organization 201991818 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.